{"id":"766748ba-e7ce-4860-9603-2b77dde9e286","modelId":"2f847d21-9b21-4ce0-bb03-6d2bd97ae10b","versionId":null,"locationId":"aa8b9c05-c836-4021-801f-59801970401e","operatorId":"4421900a-d71f-407e-a37c-ad1e3905e97f","ownerId":null,"slug":"rewalk-7-united-states","status":"operational","firstSeen":null,"statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":null,"shiftStructure":null,"hoursPerDay":null,"siteType":null,"operatorConfirmed":false,"humanSupervisionOnsite":null,"locationPrecisionTier":null,"deploymentScale":null,"siteEnvironment":null,"operatorType":"maker_operated","sourceQualityTier":null,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://ir.golifeward.com/news-releases/news-release-details/fda-issues-clearance-rewalk-7-exoskeleton","title":"FDA Issues Clearance for ReWalk 7 Exoskeleton","sourceName":"Lifeward"},{"url":"https://golifeward.com/blog/lifewards-rewalk-personal-exoskeleton-now-covered-by-aetna-coverage-expands-to-include-three-of-the-largest-medicare-advantage-insurers/","title":"Lifeward's ReWalk Personal Exoskeleton Now Covered by Aetna","sourceName":"Lifeward"}],"notes":"ReWalk 7 (FDA cleared March 2025) is the latest generation personal exoskeleton for spinal-cord-injury users. Major reimbursement milestones in 2025-2026: UnitedHealthcare (Nov 2025), Humana (Dec 2025), and Aetna (Feb 2026) Medicare Advantage prior authorizations cover ~16M beneficiaries. CMS 2024 Home Health PPS Rule created lump-sum reimbursement pathway. June 2025 ALJ ruling established precedent that personal exoskeletons are 'reasonable and necessary.' Only FDA-cleared personal exoskeleton with stairs/curbs capability. Home use and clinical deployment across the US.","keyFacts":[{"label":"FDA clearance","value":"ReWalk 7 cleared March 2025"},{"label":"Medicare Advantage coverage","value":"Aetna (Feb 2026), Humana (Dec 2025), UnitedHealthcare (Nov 2025) — ~16M beneficiaries total"},{"label":"CMS pathway","value":"2024 Medicare Home Health PPS Rule placed personal exoskeletons in brace benefit category, effective Jan 1 2024"},{"label":"ALJ precedent","value":"June 2025: Administrative Law Judge ruled ReWalk 'reasonable and necessary' for Medicare beneficiary"},{"label":"Capability","value":"Only personal exoskeleton cleared for stairs and curbs"}],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-06-07T13:21:38.390Z","updatedAt":"2026-07-22T03:47:59.759Z","model":{"id":"2f847d21-9b21-4ce0-bb03-6d2bd97ae10b","companyId":"4421900a-d71f-407e-a37c-ad1e3905e97f","modelName":"ReWalk 7","slug":"rewalk-7","description":"Powered lower-limb personal exoskeleton; latest ReWalk generation, FDA cleared March 2025. Motor-driven powered gait for spinal-cord-injury users.","formFactor":"exoskeleton","industryVertical":null,"environment":null,"maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{"use":"medical (personal, SCI)","control":"weight-shift triggered powered gait","powered":"yes (motor-driven)","regulatory":"FDA cleared 2025-03","body_region":"lower-limb","availability":"commercial (2025 launch)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://ir.golifeward.com/news-releases/news-release-details/fda-issues-clearance-rewalk-7-exoskeleton","title":"ReWalk 7 (FDA clearance 2025)","sourceName":"Lifeward (primary)"},{"url":"https://golifeward.com/","title":"Lifeward (official)","sourceName":"Lifeward (primary)"}],"aliases":["ReWalk 7"],"collisionRisk":"low","reviewNote":"reverified 2026-06-09 (Kimi-incident remediation): cited primary source resolves and matches manufacturer/reputable domain; relevance adjudicated.","manufacturerTermForTeleop":null,"keyFacts":[{"label":"Type","value":"Exoskeleton for rehabilitation"}],"createdAt":"2026-06-06T01:25:40.609Z","updatedAt":"2026-07-08T20:09:21.124Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":null,"autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"4421900a-d71f-407e-a37c-ad1e3905e97f","name":"Lifeward","slug":"lifeward","description":"Lifeward (formerly ReWalk Robotics, Nasdaq: LFWD) is an Israeli-American medical device company founded in 2001 by Dr. Amit Goffer, a quadriplegic inventor who developed the exoskeleton after an ATV accident. The company designs and commercializes powered exoskeleton systems for individuals with spinal cord injury, including the ReWalk 7 Personal Exoskeleton (FDA-cleared March 2025) and the ReWalk Personal 6.0. Lifeward's portfolio also includes the AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, with operations in the US, Israel, and Germany.","status":"public (NASDAQ: LFWD; formerly ReWalk Robotics, RWLK)","founded":2001,"hq":"Marlborough, MA, USA / Yokneam Ilit, Israel","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://ir.rewalk.com/news-releases/news-release-details/rewalk-robotics-transforms-company-identity-rebrands-lifeward","title":"Lifeward","sourceName":"Lifeward (primary)"},{"url":"https://golifeward.com/blog/rewalk-personal-exoskeleton-system-clearned-fda-home-use/","title":"ReWalk Personal 6.0 FDA home-use","sourceName":"Lifeward (primary)"},{"url":"https://ir.rewalk.com/news-releases/news-release-details/lifeward-names-mark-grant-new-ceo","label":"Lifeward Names Mark Grant as New CEO","title":"Lifeward Names Mark Grant as New CEO","mediaType":"article","sourceName":"Lifeward (official IR)"},{"url":"https://golifeward.com/blog/lifeward-launches-sales-of-the-rewalk-7-personal-exoskeleton-in-u-s-market/","label":"Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market","title":"Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market","mediaType":"article","sourceName":"Lifeward (official)"},{"url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891325000736/zk2532799.htm","label":"Lifeward Ltd. SEC Filing 2025","title":"Lifeward Ltd. SEC Filing 2025","mediaType":"article","sourceName":"SEC EDGAR"}],"keyFacts":[{"label":"CEO","value":"Mark Grant (since June 2025)"},{"label":"Previous CEO","value":"Larry Jasinski"},{"label":"CFO","value":"Mike Lawless"},{"label":"Founder","value":"Dr. Amit Goffer (deceased) — quadriplegic Israeli inventor"},{"label":"Ticker","value":"NASDAQ: LFWD"},{"label":"Revenue 2024","value":"Approximately 25.3 million USD"},{"label":"Units deployed","value":"131 rehabilitation units + 689 personal exoskeleton units (as of Dec 2024)"},{"label":"FDA clearance","value":"ReWalk 7 cleared March 2025; first FDA-cleared exoskeleton in 2014"},{"label":"Medicare","value":"CMS reimbursement pathway established 2024"},{"label":"Operations","value":"United States, Israel, Germany"},{"label":"Product portfolio","value":"ReWalk 7, ReWalk Personal 6.0, AlterG Anti-Gravity, ReStore Exo-Suit, MyoCycle FES"}],"aliases":["ReWalk Robotics","ReWalk"],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":"LFWD","stockExchange":"NASDAQ","secCik":"0001607962","revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-06T01:25:37.810Z","updatedAt":"2026-07-22T17:17:53.250Z"}},"version":null,"location":{"id":"aa8b9c05-c836-4021-801f-59801970401e","name":"United States","slug":"united-states","kind":"country","parentLocationId":null,"region":null,"lat":37.0902,"lng":-95.7129,"reviewStatus":"reviewed","aliases":["USA","US","United States of America"],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-05-30T22:00:33.148Z","updatedAt":"2026-07-04T13:32:31.997Z"},"operator":{"id":"4421900a-d71f-407e-a37c-ad1e3905e97f","name":"Lifeward","slug":"lifeward","description":"Lifeward (formerly ReWalk Robotics, Nasdaq: LFWD) is an Israeli-American medical device company founded in 2001 by Dr. Amit Goffer, a quadriplegic inventor who developed the exoskeleton after an ATV accident. The company designs and commercializes powered exoskeleton systems for individuals with spinal cord injury, including the ReWalk 7 Personal Exoskeleton (FDA-cleared March 2025) and the ReWalk Personal 6.0. Lifeward's portfolio also includes the AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, with operations in the US, Israel, and Germany.","status":"public (NASDAQ: LFWD; formerly ReWalk Robotics, RWLK)","founded":2001,"hq":"Marlborough, MA, USA / Yokneam Ilit, Israel","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://ir.rewalk.com/news-releases/news-release-details/rewalk-robotics-transforms-company-identity-rebrands-lifeward","title":"Lifeward","sourceName":"Lifeward (primary)"},{"url":"https://golifeward.com/blog/rewalk-personal-exoskeleton-system-clearned-fda-home-use/","title":"ReWalk Personal 6.0 FDA home-use","sourceName":"Lifeward (primary)"},{"url":"https://ir.rewalk.com/news-releases/news-release-details/lifeward-names-mark-grant-new-ceo","label":"Lifeward Names Mark Grant as New CEO","title":"Lifeward Names Mark Grant as New CEO","mediaType":"article","sourceName":"Lifeward (official IR)"},{"url":"https://golifeward.com/blog/lifeward-launches-sales-of-the-rewalk-7-personal-exoskeleton-in-u-s-market/","label":"Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market","title":"Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market","mediaType":"article","sourceName":"Lifeward (official)"},{"url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891325000736/zk2532799.htm","label":"Lifeward Ltd. SEC Filing 2025","title":"Lifeward Ltd. SEC Filing 2025","mediaType":"article","sourceName":"SEC EDGAR"}],"keyFacts":[{"label":"CEO","value":"Mark Grant (since June 2025)"},{"label":"Previous CEO","value":"Larry Jasinski"},{"label":"CFO","value":"Mike Lawless"},{"label":"Founder","value":"Dr. Amit Goffer (deceased) — quadriplegic Israeli inventor"},{"label":"Ticker","value":"NASDAQ: LFWD"},{"label":"Revenue 2024","value":"Approximately 25.3 million USD"},{"label":"Units deployed","value":"131 rehabilitation units + 689 personal exoskeleton units (as of Dec 2024)"},{"label":"FDA clearance","value":"ReWalk 7 cleared March 2025; first FDA-cleared exoskeleton in 2014"},{"label":"Medicare","value":"CMS reimbursement pathway established 2024"},{"label":"Operations","value":"United States, Israel, Germany"},{"label":"Product portfolio","value":"ReWalk 7, ReWalk Personal 6.0, AlterG Anti-Gravity, ReStore Exo-Suit, MyoCycle FES"}],"aliases":["ReWalk Robotics","ReWalk"],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":"LFWD","stockExchange":"NASDAQ","secCik":"0001607962","revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-06T01:25:37.810Z","updatedAt":"2026-07-22T17:17:53.250Z"},"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/rewalk-7-united-states","url":"https://registry.deploy.report/deployments/rewalk-7-united-states","name":"ReWalk 7 at United States","identifier":"766748ba-e7ce-4860-9603-2b77dde9e286","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/united-states","name":"United States"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/lifeward","name":"Lifeward"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/rewalk-7","name":"ReWalk 7"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"commercial","lifecycle_state":"active","architectural_position":{"cohort":"exoskeleton","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":2,"primary_source_types":["primary-company-ir"]}}}